Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment
The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
In 1968, DiMascio and Shader provided a conceptual framework for behavioral toxicity of psychotropic drugs (ie, the pharmacological actions of a drug that, within the dose range in which it has been found to possess clinical utility, may produce alterations in mood, perceptual, cognitive, and psychomotor functions that limit the capacity of the individual or constitute a hazard to one's well-being). A drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at one stage of one's illness and adverse at a later stage. The concept of behavioral toxicity encompasses adverse events that may be limited to the period of drug administration and/or persist long after their discontinuation. These latter phenomena can be subsumed under the rubric of iatrogenic comorbidity. Behavioral toxicity may ensue with any type of medical drug. Examples related to antidepressant drug use (onset of suicidality and aggression, switching from unipolar to bipolar course, withdrawal phenomena upon discontinuation, postwithdrawal persistent disorders) are discussed. Consideration of potential vulnerability to adverse events including behavioral toxicity should be placed in the context of the benefits that treatment may entail.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psychotropic drug treatment, particularly when it is protracted in time, may cause various forms of dependence 97 .”
From The pursuit of euthymia (2020) · cites this paper as [97]
In the citing paper
“These symptoms may constitute a iatrogenic comorbidity that affects the course of illness and the response to subsequent treatments 97 .”
From The pursuit of euthymia (2020) · cites this paper as [97]
In the citing paper
“A bulk of literature, derived from controlled trials [18, 110, 111], case reports [19], and patients' online reports [112], showed that new withdrawal symptoms may occur with any type of SSRI, but paroxetine is the most likely to be associated with new symptoms, while fluoxetine being the least associated.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [19]
In the citing paper
“After SSRIs long-term use, persistent post-withdrawal disorders have been described [10, 13, 18, 19, 112, 117, 118].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [19]
In the citing paper
“Randomized controlled trials (RCT) in medicine thus referred to an average patient who fulfilled the criteria for admission and ignored the patient's individual history [37].”
From The Deceptive Manifestations of Treatment Resistance in Depression: A New Look at the Problem (2020) · cites this paper as [37]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The pre-therapeutic classification of co-morbidity in chronic disease
Feinstein, A. R. (1970) · Journal of Chronic Diseases · doi:10.1016/0021-9681(70)90054-8 · Cited by 1,544 · cited 1×
“Alvan Feinstein's classic definition of comorbidity as “any distinct additional clinical entity that has existed or that may occur during the clinical course of a patient who has the index disease under study” referred also to antecedent pathological events that were judged to affect the current disease process.(20) T…”
BackgroundFava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436 · cited 2×
“The following psychological symptoms may ensue as well: agitation, anxiety, panic attacks, dysphoria, confusion, and worsening of mood.(16,17) Symptoms typically appear within 3 days of stopping antidepressant medication or initiating a medication taper.”
BackgroundSelf-citationAdverse Drug Reactions: A Critical Review
Karch, F. E. (1975) · JAMA · doi:10.1001/jama.1975.03260250028021 · Cited by 335
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Mania associated with antidepressant treatment: comprehensive meta‐analytic review
Tondo, L., Vázquez, G., & Baldessarini, R. J. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01514.x · Cited by 256 · cited 1×
“Treatment with ADs has been associated with mania or other forms of excessive behavioral activation.(12) These responses may unveil unrecognized bipolar illness or may be drug related, because they may also occur in allegedly unipolar patients.”
BackgroundStaging of Mental Disorders: Systematic Review
Cosci, F., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000342243 · Cited by 235 · cited 1×
“Such role is influenced by the clinical stage of development of a disorder.(27,28) Indeed, DiMascio and Shader(1) noted that a drug effect such as sedation or motor stimulation may be considered adverse for one patient and yet therapeutic and desired for another patient; within the same patient, it may be of value at…”
BackgroundSelf-citationGuidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167 · cited 1×
“Not surprisingly, the sequential application of psychotherapy in depressed patients who remitted upon drug treatment has yielded its best results when ADs were tapered and discontinued.(36)”
ResultSelf-citationNew Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164 · cited 3×
“The following psychological symptoms may ensue as well: agitation, anxiety, panic attacks, dysphoria, confusion, and worsening of mood.(16,17) Symptoms typically appear within 3 days of stopping antidepressant medication or initiating a medication taper.”
BackgroundBehavioral toxicity of antipsychotic drugs.
Putten, T. V., & Marder, S. R. (1987) · PubMed · Cited by 144
Vandenbroucke, J. P., & Psaty, B. M. (2008) · JAMA · doi:10.1001/jama.2008.723 · Cited by 131
Cited by
Solmi, M., Murru, A., Pacchiarotti, I., Undurraga, J., Veronese, N., Fornaro, M., Stubbs, B., Monaco, F., Vieta, E., Seeman, M., et al. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s117321 · Cited by 438
“Importantly, some of these untoward effects may persist long after drug discontinuation.(50,51) Such phenomena are captured by the term iatrogenic comorbidity,(50,51) a negative outcome of the treatment of psychosis whose unfortunate pervasiveness is this review hopes to reduce.”
Current Psychosomatic Practice
Fava, G. A., Cosci, F., & Sonino, N. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448856 · Cited by 302
Self-citationAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Self-citationMethodological Recommendations for Trials of Psychological Interventions
Guidi, J., Brakemeier, E.-L., Bockting, C. L. H., Cosci, F., Cuijpers, P., Jarrett, R. B., Linden, M., Marks, I., Peretti, C. S., Rafanelli, C., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000490574 · Cited by 205
Self-citation
Metadata
- Authors
- Fava, G. A., Cosci, F., Offidani, E., & Guidi, J.
- Affiliations
- Cornell University (US)
- Corresponding author
- Fava, Giovanni A.
- Guidi, Jenny
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-12
- Volume
- 36
- Issue
- 6
- Pages
- 550-553
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2520453977
- Cited by
- 55
- References
- 38
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 8 · 2020: 11 · 2019: 8 · 2018: 8 · 2017: 6 · 2016: 2
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- behavioral toxicity, psychotropic drugs, adverse drug reactions, antidepressants, suicidality, aggression, bipolar disorder, antidepressant discontinuation, patient vulnerability
- MeSH terms
- Mental Disorders, Humans, Iatrogenic Disease, Psychotropic Drugs, Comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment. https://app.cochat.ai/papers/10.1097/jcp.0000000000000570
- The paper
- Fava, G. A., Cosci, F., Offidani, E., & Guidi, J. (2016). Behavioral Toxicity Revisited: Iatrogenic Comorbidity in Psychiatric Evaluation and Treatment. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000570
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.